Holen Sie sich die Stockscreener-App
30.68
6.64%
1.91
Handel nachbörslich:
29.94
-0.74
-2.41%
Schlusskurs vom Vortag:
$28.77
Offen:
$29.14
24-Stunden-Volumen:
2.73M
Relative Volume:
1.93
Marktkapitalisierung:
$2.41B
Einnahmen:
$399.58M
Nettoeinkommen (Verlust:
$-54.04M
KGV:
-40.91
EPS:
-0.75
Netto-Cashflow:
$40.13M
1W Leistung:
+27.99%
1M Leistung:
+13.29%
6M Leistung:
-22.51%
1J Leistung:
-5.75%
1-Tages-Spanne:
$28.91
$30.73
1-Wochen-Bereich:
$25.52
$30.73
52-Wochen-Spanne:
$22.61
$47.32
Veracyte Inc Stock (VCYT) Company Profile
Firmenname
Veracyte Inc
Sektor
Branche
Telefon
(650) 243-6300
Adresse
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Vergleichen Sie VCYT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
30.68 | 2.20B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
484.79 | 174.60B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
209.14 | 143.04B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
663.92 | 52.17B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
120.29 | 32.42B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
190.23 | 30.62B | 15.50B | 1.33B | 2.16B | 7.34 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-20 | Eingeleitet | Craig Hallum | Buy |
| 2024-12-05 | Herabstufung | Goldman | Buy → Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-16 | Eingeleitet | UBS | Buy |
| 2024-10-10 | Eingeleitet | Guggenheim | Buy |
| 2024-02-23 | Bestätigt | Needham | Buy |
| 2023-01-18 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2021-11-18 | Fortgesetzt | Goldman | Buy |
| 2021-06-15 | Eingeleitet | Raymond James | Outperform |
| 2021-02-18 | Fortgesetzt | Needham | Buy |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Underweight |
| 2019-07-31 | Eingeleitet | Lake Street | Buy |
| 2019-07-02 | Eingeleitet | Needham | Buy |
| 2018-11-29 | Herabstufung | Janney | Buy → Neutral |
| 2018-10-31 | Hochstufung | Janney | Neutral → Buy |
| 2017-11-07 | Herabstufung | Janney | Buy → Neutral |
| 2017-11-07 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | Fortgesetzt | BTIG Research | Buy |
| 2016-11-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-12-18 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-06-11 | Bestätigt | Leerink Partners | Outperform |
| 2013-11-26 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Veracyte Inc Aktie (VCYT) Neueste Nachrichten
VCYT Stock Gains on Q2 Earnings and Revenue Beat, Margins Up - TradingView
Candlestick Signal Suggests Reversal in Veracyte Inc.Chart-Based Trade Entries Gain Analyst Support - metal.it
Veracyte stock price target lowered to $28 from $29 at Morgan Stanley - Investing.com Nigeria
Cautious Outlook on Veracyte: Sell Rating Amid Market Uncertainties and Valuation Concerns - TipRanks
Veracyte price target lowered to $28 from $29 at Morgan Stanley - TipRanks
A Quick Look at Today's Ratings for Veracyte(VCYT.US), With a Forecast Between $41 to $45 - 富途牛牛
Veracyte, Inc. (NASDAQ:VCYT) Q2 2025 Earnings Call Transcript - Insider Monkey
Decoding Veracyte Inc (VCYT): A Strategic SWOT Insight - GuruFocus
Veracyte Inc’s Earnings Call Highlights Robust Growth and Strategic Milestones - TipRanks
Veracyte Receives Buy Rating and $37 Price Target from Guggenheim Analyst - AInvest
Veracyte’s Strong Financial Performance and Promising Growth Prospects Justify Buy Rating - TipRanks
Helix and Veracyte Partner to Expand Access to Clinically Actionable Genomic Insights in Prostate Cancer Care - AInvest
Veracyte (VCYT) Q2 Revenue Jumps 14% - AOL.com
Veracyte stock rating reiterated at Outperform by William Blair - Investing.com India
Earnings call transcript: Veracyte’s Q2 2025 earnings beat expectations, stock falls - Investing.com Canada
Earnings call transcript: Veracyte’s Q2 2025 earnings beat expectations, stock falls By Investing.com - Investing.com South Africa
Veracyte: Q2 Earnings Snapshot - Greenwich Time
Veracyte's 2025 Q2 Financial Performance and Strategic Momentum: A Deep Dive into Diagnostic Innovation and Oncology Expansion - AInvest
Veracyte Announces Second Quarter 2025 Financial Results - BioSpace
Veracyte's 2025 Earnings Call: A Catalyst-Driven Path to Sustained Double-Digit Growth and 25%+ Adjusted EBITDA Margins - AInvest
Veracyte Reports Strong Q2 2025 Revenue Growth - TipRanks
Veracyte’s Revenue Growth Outpaces Forecasts And Lifts Guidance - Finimize
Veracyte (VCYT) Tops Q2 Earnings and Revenue Estimates - Yahoo Finance
Veracyte Q2 2025 slides: Decipher drives 14% revenue growth, EBITDA margins expand - Investing.com Nigeria
Veracyte Q2 revenue rises 14%, beats expectations - MarketScreener
Veracyte Inc (VCYT) Q2 2025 Earnings: Revenue Surpasses Estimates at $130.2M, Reports GAAP Net Loss - GuruFocus
Veracyte shares surge as Q2 profits quadruple expectations By Investing.com - Investing.com Nigeria
Veracyte Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Veracyte shares surge as Q2 profits quadruple expectations - Investing.com
Veracyte Inc earnings beat by $0.33, revenue topped estimates - Investing.com Canada
Veracyte reports Q2 EPS 44c, consensus 30c - TipRanks
Veracyte sees FY25 revenue $477M-$483M, consensus $491.92M - TipRanks
Earnings Flash (VCYT) Veracyte, Inc. Reports Q2 Revenue $130.2M, vs. FactSet Est of $121.0M - MarketScreener
Earnings Flash (VCYT) Veracyte, Inc. Posts Q2 Adjusted EPS $0.44 per Share, vs. FactSet Est of $0.26 - MarketScreener
Press Release: Veracyte Announces Second Quarter 2025 Financial Results - 富途牛牛
Veracyte Q2 2025 Earnings Call Transcript - MarketBeat
Veracyte Inc (VCYT) Q2 2025 Earnings Report Preview: What to Look For - Yahoo Finance
What catalysts could drive Veracyte Inc. stock higher in 2025Invest smarter with daily market updates - Jammu Links News
How does Veracyte Inc. compare to its industry peersFree Stock Market Trend Analysis - Jammu Links News
How does Veracyte Inc. generate profit in a changing economyMaximize portfolio growth with strategic plans - Jammu Links News
How many analysts rate Veracyte Inc. as a “Buy”Invest confidently with professional market insights - Jammu Links News
Should I hold or sell Veracyte Inc. stock in 2025Achieve consistent double-digit growth rates - Jammu Links News
What is the risk reward ratio of investing in Veracyte Inc. stockUnlock exclusive investment alerts - Jammu Links News
How strong is Veracyte Inc. company’s balance sheetOutstanding capital appreciation - Jammu Links News
What is the dividend policy of Veracyte Inc. stockSuperior risk-adjusted returns - Jammu Links News
What drives Veracyte Inc. stock priceUnprecedented market success - Jammu Links News
What institutional investors are buying Veracyte Inc. stockInvest confidently with data-backed picks - Jammu Links News
Is it the right time to buy Veracyte Inc. stockBuild a balanced portfolio for long-term success - Jammu Links News
When is Veracyte Inc. stock expected to show significant growthCapitalize on market momentum for maximum gains - Jammu Links News
What are analysts’ price targets for Veracyte Inc. in the next 12 monthsSuperior trading gains - Jammu Links News
Finanzdaten der Veracyte Inc-Aktie (VCYT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Veracyte Inc-Aktie (VCYT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bhanji Muna | Director |
Jun 13 '25 |
Sale |
26.67 |
4,589 |
122,367 |
29,989 |
3.96%
1.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):